Hypericum perforatum Subspecies Angustifolium shows a Protective Activity on the Consequences of Unavoidable Stress Exposure at Lower Doses than Hypericum perforatum Perforatum

Pharmacopsychiatry

Volumn 36, Issue 6, 2003, Pages 283-287

  Usai, M ^a   Leggio, B ^b   Grappi, S ^b   Nanni, G ^b   Gambarana, C ^b   Tolu, P ^b   Giachetti, D ^b   De Montis, M G ^a,b  

^a UNIVERSITY OF SASSARI   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; HYPERFORIN; HYPERICUM PERFORATUM EXTRACT; HYPERICUM PERFORATUM PERFORATUM EXTRACT; IMIPRAMINE; PLANT EXTRACT; TERPENE; UNCLASSIFIED DRUG;

ANIMAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DEPRESSION; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; HYPERICUM; HYPERICUM PERFORATUM; HYPERICUM PERFORATUM PERFORATUM; LONG TERM EXPOSURE; LOW DRUG DOSE; MALE; MEDICINAL PLANT; MENTAL STRESS; NEUROPROTECTION; NONHUMAN; PHYTOTHERAPY; PRIORITY JOURNAL; PSYCHIATRIC TREATMENT; PSYCHOLOGICAL ASPECT; RAT; RAT STRAIN; STIMULUS RESPONSE; STRESS;

ANIMALS; ANTIDEPRESSIVE AGENTS; BICYCLO COMPOUNDS; DEPRESSION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPERICUM; IMIPRAMINE; MALE; PHLOROGLUCINOL; PHYTOTHERAPY; PLANT EXTRACTS; PLANTS, MEDICINAL; RATS; RATS, SPRAGUE-DAWLEY; STRESS, PSYCHOLOGICAL; TERPENES;

EID: 0347634428     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-45114     Document Type: Article

References (37)

1. Battacharya S-K, Chakrabarti A, Chatterjee S-S. Activity profiles of two hyperforin-containing hypericum extracts in behavioral models. Pharmacopsychiatry 1998; 31 Suppl 2: 22-29
2. Bombardelli E, Morazzoni P. Hypericum perforatum. Fitoterapia 1995; 66: 43-68
3. Brolis M, Gabetta B, Fuzzati N, Pace R, Panzeri F, Peterlongo F. Identification by high-performance liquid chromatography-diode array detection-mass spectrometry and quantification by high-performance liquid chromatography-UV absorbance detection of active constituents of Hypericum perforatum. J Cromatography A 1998; 825: 9-16
4. Butterweck V, Wall A, Liefländer-Wulf U, Winterhoff H, Nahrstedt A. Effects of the total extract and fractions of Hypericum perforatum in animal assays for antidepressant activity. Pharmacopsychiatry 1997; 30 Suppl 2: 117-124
5. Butterweck V, Petereit F, Whinterhoff H, Nahrstedt A. Solubilized hypericin and pseudohypericin from Hypericum perforatum exert antidepressant activity in the forced swimming test. Planta Med 1998; 64: 291-294
6. Butterweck V, Jurgenliemk G, Nahrstedt A, Vinterhoff H. Flavonoids from Hypericum perforatum show antidepressant activity in the forced swimming test. Planta Med 2000; 66 (1): 3-6
7. Butterweck V, Korte B, Winterhoff H. Pharmacological and endocrine effects of Hypericum perforatum and hypericin after repeated treatment. Pharmacopsychiatry 2001; 34 Suppl 1: 2-7
8. Cappelletti C. In: "Botanica" sistematica , UTET Torino. 1965; 2: 1372
9. Chatterjee SS, Koch E, Nöldner M, Biber A, Erdelmeier C. Hyperforin and hypericum extract: Interaction with some neurotransmitter systems. Phytomedicine 1996; 3 Suppl 1: 106
10. Chatterjee SS, Bhattacharya SK, Wonnemann M, Singer A, Müller WE. Hyperforin as a possible antidepressant component of hypericum extracts. Life Sci 1998; 63: 499-510
11. Chatterjee SS, Nöldner M, Koch C, Erdelmeier C. Antidepressant activity of Hypericum perforatum and hyperforin: the neglected possibility. Pharmacopsychiatry 1998; 31: 7-15
12. De Montis MG, Gambarana C, Ghiglieri O, Tagliamonte A. Reversal of stable behavioural modifications through NMDA receptor inhibition in rats. Behav Pharmacol 1995; 6: 562-567
13. De Smet PAGM, Nolen WA. St John's wort as an antidepressant. Br Med J 1996; 313: 241-242
14. Erdelmeier CAJ. Hyperforin, possibly the major non-nitrogenous secondary metabolite of Hypericum perforatum L. Pharmacopsychiatry 1998; 31: 2-6
15. Ernst E. St. John's wort, an antidepressant? A systematic, criteria-based review. Phytomedicine 1995; 2: 7-71
16. Gambarana C, Ghiglieri O, Taddei I, Tagliamonte A, De Montis MG. Imipramine and fluoxetine prevent the stress-induced escape deficits in rats through a distinct mechanism of action. Behav Pharmacol 1995; 6: 66-73
17. Gambarana C, Ghiglieri O, Tolu P, De Montis M.G, Giachetti D, Bombardelli E, Tagliamonte A. Efficacy of an Hypericum perforatum (St. John's wort) extract in preventing and reverting a condition of escape deficit in rats. Neuropsychopharmacol 1999; 21: 247-257
18. Gambarana C, Scheggi S, Tagliamonte A, Tolu P, De Montis MG. Animal models for the study of antidepressant activity. Brain Res Prot 2001; 7: 11-20
19. Gambarana C, Tolu PL, Masi F, Rinaldi M, Giachetti D, Morazzoni P, De Montis MG. A study of the antidepressant activity of Hypericum perforatum on animal models. Pharmacopsychiatry 2001; 34: 42-44
20. Gambarana C, Grappi S, Nanni G. Dose-dependent antidepressant activity of hyperforin in rats. Soc Neurosci Abs, 2001; 27: Program No. 975.12
21. Gobbi M, Mennini T. Is St John's wort a "Prozac like" herbal antidepressant? TIPS 2001; 22: 557-559
22. Hotopf M. St. John's wort is more effective than placebo for treating depressive disorders. Evidence-Based Med 1999; 4: 82
23. Laakmann G, Schüle C, Baghai T, Kieser M. St. John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy. Pharmacopsychiatry 1998; 31 Suppl: 54-59
24. Linde K, Ramirez G, Mulrow C. D, Pauls A, Weidenhammer W. Melchart D. St John's wort for depression-an overview and meta-analysis of randomised clinical trials. Br Med J 1996; 313: 253-258
25. Linde K, Mulrow CD. St John's wort for depression (Cochrane Review). In: The Cochrane Library. 2002; Issue 2 Oxford:
26. Müller WE, Rolli M, Schäfer C, Hafner U. Effects of hypericum extract (Li160) in biochemicals models of antidepressant activity. Pharmacopsychiatry 1997; 30 Suppl 2: 102-107
27. Müller W.E, Singer A, Wonnemann M, Hafner U, Rolli M, Schäfer C. Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum extract. Pharmacopsychiatry 1998; 31 Suppl 1: 16-21
28. Müller VE, Singer A, Wonnemann M. Hyperforin - antidepressant activity by a novel mechanism of action. Pharmacopsychiatry 2001; 34 Suppl 1: 98-102
29. Nahrstedt A, Butterweck V. Biological activity and other chemical constituents of the herb of Hypericum perforatum L. Pharmacopsychiatry 1997; 30 Suppl 2: 129-134
30. Nöldner M. Antidepressive Effekte von Johannlskrauteextract und wichtigen Inhaltsstoffen im Tiermodell. In: Behandlung von depressiven Patienten in der täglichen Praxis Stellenwert von Joanniskrautextrakt W. E. Müller & M. Gatspar (Hrsg). Neu- Isenburg: LinguaMed-Verlag GmbH, 2001
31. Nöldner M, Schötz K. Rutin is essential for the antidepressant activity of Hypericum perforatum extracts in the forced swimming test. Planta Med 2002; 68: 577-580
32. Philipp M, Kohnen R, Hiller K-O. Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks. Br Med J 1999; 319: 1534-1539
33. Shelton RC, Keller MB, Gelenberg A, Dunner DL, Hirschfeld R, Thase ME, Russell J, Lydiard RB, Crits-Cristoph P, Gallop R, Todd L, Hellerstein D, Goodnick P, Keitner G, Stahl SM, Halbreich U. Effectiveness of St John's wort in major depression: a randomized controlled trial. JAMA 2001; 285: 1978-1986
34. Tekel'ova D, Repcak M, Zemkova E, Toth J. Quantitative changes of dianthrones, hyperforin and flavonoids content in the flower ontogenesis of Hypericum perforatum. Planta Med 2000; 66: 778-780
35. Volz HP. Controlled clinical trials of hypericum extracts in depressed patients - an overview. Pharmacopsychiatry 1997; 30 Suppl 2: 72-76
36. Wheatly D. Hypericum extract-potential in the treatment of depression. CNS Drugs 1998; 9: 431-440
37. Wonnemann M, Singer A, Müller WE Inhibition of synaptosomal uptake of 3H-L-glutamate and 3H-GABA by hyperforin, a major constituent of St. John's Wort. The role of amiloride sensitive sodium conductive patways. Neuropsychopharmacology 2000; 23: 188-197